

Subject: Specialised Services Circular (SSC)

Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2866	NHS England Clinical Commissioning Policy: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages) URN2333	University Hospitals Bristol and Weston Foundation Trust

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? **No**

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

All Chief Executives

All Medical Directors

All Chief Pharmacists

Specialised Commissioning South West
NHS England
100 Temple Street
Bristol
BS1 6AG
Email: england.speccomm-southwest@nhs.net

8 August 2025

Dear Colleagues,

Re: NHS England Clinical Commissioning Policy: Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages) URN2333

I am writing to advise you regarding the funding position on the recently published NHS England Clinical Commissioning Policy (CCP) for emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages).

The CCP can be found at: [NHS England » Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors](#)

Emicizumab will be routinely commissioned from 31st July in line with the CCP and the stated eligibility treatment criteria.

In addition:

- Trusts must ensure that they are purchasing emicizumab at the agreed NHS framework price. This price will be applied automatically at point of invoice and applies to all indications. The price paid by Trusts remains the same as the existing price.
- Trusts must ensure that only invoices for the drug procurement costs of emicizumab in this indication are invoiced to NHSE and that they are also submitting complete and accurate information via the high-cost drugs minimum dataset (MDS). All other on costs are in block arrangements.
- In line with the terms and conditions included in the NHS Standard Contract Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the drug MDS record and this information being made available in a timely way.
- Patients must be registered via Blueteq initiation form and meet the clinical criteria on the registration form. This letter gives the required one month's notice as per Schedule 2 Part G (Other Local Agreements, Policies and Procedures) of your Specialised Services contract for prior approval for this treatment/indication. From


one month of the date specified above, NHS England will only reimburse these treatments for patients that have been confirmed as meeting the eligibility criteria via the formal Prior Approval Scheme (i.e. Blumetq). You may wish to use the prior approval mechanism earlier than this to expedite access to this drug.

- Payment of Trust invoices will be contingent on Blumetq registration and the high-cost drug MDS record applicable to the drug being completed and this information being made available in a timely way.
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.


Trusts should refer to the relevant MPSC NHS National Framework Agreement for the correct price of emicizumab.

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

With best wishes,



Emma Redfern
Medical Director NHS England South West
Region



Tracey Williams
Principal Pharmacist